Detalhe da pesquisa
1.
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.
Blood;
143(7): 592-596, 2024 Feb 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38048557
2.
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Lancet Oncol;
24(1): 64-76, 2023 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36528035
3.
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study.
Lancet Oncol;
24(10): 1119-1133, 2023 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37717583
4.
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Lancet Oncol;
22(12): 1705-1720, 2021 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34774221
5.
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial.
Haematologica;
105(7): 1937-1947, 2020 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31582542
6.
Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma.
Biol Blood Marrow Transplant;
24(7): 1372-1378, 2018 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29408334
7.
Peripheral blood CD34+ percentage at hematological recovery after chemotherapy is a good early predictor of harvest: a single-center experience.
Biol Blood Marrow Transplant;
20(5): 717-23, 2014 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24525280
8.
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Blood;
120(1): 9-19, 2012 Jul 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22498745
9.
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.
Blood;
118(22): 5759-66, 2011 Nov 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21951682
10.
Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy.
Haematologica;
103(10): e469-e472, 2018 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29700168
11.
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial.
EClinicalMedicine;
60: 102017, 2023 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37396807
12.
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.
Blood;
116(23): 4745-53, 2010 Dec 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20807892
13.
Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study.
Blood;
115(10): 1873-9, 2010 Mar 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19965659
14.
Immune dysfunctions affecting bone marrow Vγ9Vδ2 T cells in multiple myeloma: Role of immune checkpoints and disease status.
Front Immunol;
13: 1073227, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36605214
15.
Diagnosis of maternal Hodgkin lymphoma following abnormal findings at noninvasive prenatal screening test (NIPT): Report of two cases.
Clin Case Rep;
9(3): 1066-1071, 2021 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33768784
16.
The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma.
Pharmaceuticals (Basel);
14(1)2020 Dec 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33383757
17.
Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports.
J Med Case Rep;
14(1): 75, 2020 Jun 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32564775
18.
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Lancet Haematol;
7(6): e456-e468, 2020 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32359506
19.
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial.
J Hematol Oncol;
12(1): 4, 2019 01 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30626425
20.
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Lancet;
367(9513): 825-31, 2006 Mar 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16530576